Status:

UNKNOWN

HemosprayTM for Gastrointestinal Bleeding From Cancer

Lead Sponsor:

King Chulalongkorn Memorial Hospital

Conditions:

Gastrointestinal Bleeding From Malignancy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Title: The efficacy of hemostatic powder TC-325 versus standard endoscopic treatment for gastrointestinal bleeding from malignancy; a multi-center randomized trial Background: Gastrointestinal (GI) b...

Eligibility Criteria

Inclusion

  • Acute upper or lower gastrointestinal bleeding
  • Endoscopy shows actively bleeding at index endoscopy (spurting or oozing)
  • Bleeding from malignancy

Exclusion

  • Less than 18 years old
  • Previously included in the trial
  • Eastern Cooperative Oncology Group (ECOG) score 3 or 4
  • Pregnancy/lactation
  • Bleeding from GI sources suspected of not being malignant

Key Trial Info

Start Date :

June 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

112 Patients enrolled

Trial Details

Trial ID

NCT03855904

Start Date

June 1 2019

End Date

December 31 2022

Last Update

October 4 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

King Chulalongkorn Memorial Hospital

Bangkok, Thailand, 10330

HemosprayTM for Gastrointestinal Bleeding From Cancer | DecenTrialz